Loading
Loading
LY3437943 · Triple agonist: GLP-1 / GIP / Glucagon
The most advanced triple-receptor agonist in clinical development. Phase II trials showed up to 24.2% mean body weight reduction at 48 weeks — outpacing both semaglutide and tirzepatide in head-to-head context.
⚠️ Official Health Alert — Victorian Dept of Health, 19 June 2026
Six cases of acute liver toxicity have been reported in Victoria in people who used products labelled Retatrutide. Investigations suggest the toxicity is likely caused by a contaminant in affected products, not Retatrutide itself — however the source of contamination has not yet been identified and all labelled products are considered at risk.
The Chief Health Officer advises: do not use any product labelled Retatrutide, Reta, R-10 or R-20. Anyone who has purchased such a product should stop use immediately and dispose of it safely.
All Capital Precision Labs products are independently third-party tested for purity and sourced from verified suppliers. If you have sourced Retatrutide from any other supplier, please exercise particular caution — the affected cases are believed to involve products purchased through unverified online or social media channels.
Symptoms to watch for: tiredness, jaundice, abdominal pain, dark urine, itchy skin, yellow eyes or skin, unusual bruising. Seek medical attention immediately if any occur.
Victorian Poisons Information Centre: 13 11 26 (24/7) · Emergency: 000 · health.vic.gov.au
Retatrutide is a synthetic peptide that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. It was developed by Eli Lilly and is currently in Phase III clinical trials under the code name LY3437943.
In plain terms: GLP-1 tells your brain you're full and slows gastric emptying. GIP improves how fat tissue and muscle respond to insulin. Glucagon tells your liver to burn more fuel and raises your metabolic rate. Retatrutide fires all three signals at once — producing appetite suppression, improved insulin sensitivity, and elevated caloric burn simultaneously.
In Eli Lilly's Phase II results published in the New England Journal of Medicine (2023), participants receiving 12 mg/week lost a mean of 24.2% of body weight over 48 weeks. For comparison, semaglutide 2.4 mg achieves ~15% and tirzepatide 15 mg achieves ~20% over comparable durations.
Not on the FDA 503B compounding list
Eli Lilly trials expected to complete 2025–2026
Sold strictly as a research chemical for non-human use
GLP-1 agonists/peptide hormones are prohibited in-competition
No approved indication exists yet in any jurisdiction
In Australia, retatrutide has no TGA approval and is not available through compounding pharmacies. It is sold by Capital Precision Labs strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Retatrutide is a fatty-acid-modified peptide that binds to and activates all three receptors with balanced potency. The design challenge — and key innovation — was tuning glucagon receptor activity so that its hyperglycaemic potential is offset by the insulin-stimulating effects of GLP-1 co-activation.
GLP-1R activation
GIPR activation
GCGR activation
The sections below contain our original preclinical research overview — covering key findings from animal models, the scientific introduction, and research applications.